Pirenzepine

Pirenzepine (LS 519, Gastrozepin) is a tricyclic pyridobenzodiazepinone and the prototypical selective antagonist of the M1 subtype of the muscarinic acetylcholine receptor. Synthesized at Dr. Karl Thomae GmbH, a subsidiary of Boehringer Ingelheim, in the mid-1970s, the compound was the first muscarinic antagonist demonstrated to discriminate pharmacologically between what were subsequently classified as M1 and M2 receptor subtypes, a finding reported by Hammer et al. in 1980 in Nature and foundational to the modern subtype classification of muscarinic receptors [1]. Pirenzepine binds the M1 muscarinic receptor with a dissociation constant (Ki) of approximately 5 to 14 nanomolar and displays 5- to 20-fold selectivity over the M2, M3, and M5 subtypes, with intermediate affinity at M4 receptors [2, 3]. The compound is peripherally selective, exhibiting negligible penetration of the blood-brain barrier at therapeutic oral doses, a property that minimizes central anticholinergic adverse effects and distinguishes it from atropine and other non-selective muscarinic antagonists. The primary registered indication is peptic ulcer disease. Pirenzepine inhibits vagally mediated and pentagastrin-stimulated gastric acid secretion through antagonism of M1 receptors on intramural gastric plexus neurons, reducing basal acid output by approximately 50 percent at oral doses of 50 mg twice daily [4, 5]. Extensive controlled trials conducted through the late 1970s and 1980s demonstrated duodenal ulcer healing rates of 60 to 76 percent at 4 to 8 weeks on pirenzepine 100 to 150 mg per day, broadly comparable to cimetidine 1 g per day and superior to placebo and gefarnate [6, 7]. The compound was registered as Gastrozepin in numerous European, Asian, and Latin American jurisdictions but was never approved by the United States Food and Drug Administration. The clinical importance of pirenzepine as a gastric antisecretory agent has diminished substantially following the introduction of histamine H2 receptor antagonists and proton pump inhibitors, which offer superior acid suppression and ulcer healing rates. A second, more recent research application is the retardation of progressive myopia (axial elongation of the globe) in children aged 8 to 12 years. Two multicenter, randomized, double-masked, placebo-controlled trials of 2% pirenzepine ophthalmic gel, conducted by Siatkowski et al. (2004, 2008), demonstrated approximately 50 percent reduction in the rate of myopia progression over 1- and 2-year treatment periods, with a clinically acceptable safety profile dominated by mild pupil dilation and accommodation difficulty [8, 9]. The mechanism of the antimyopic effect is incompletely characterized but is attributed to M1 and possibly M4 muscarinic receptor antagonism in the retina and sclera, modulating signaling cascades that regulate scleral extracellular matrix remodeling and axial elongation [10]. The ophthalmic application has not received regulatory approval; the compound remains investigational for myopia control, with atropine (a non-selective muscarinic antagonist applied at low concentrations) having advanced further in clinical development for this indication. Pharmacokinetics are characterized by low oral bioavailability (20 to 30 percent in fasted subjects, further reduced by food), a plasma elimination half-life of approximately 10 to 12 hours, negligible hepatic first-pass metabolism, predominant renal elimination of unchanged drug, and low plasma protein binding (approximately 12 percent) [11, 12]. The compound does not undergo significant cytochrome P450-mediated metabolism and has a correspondingly limited drug-drug interaction profile. The principal adverse events at registered oral doses are mild anticholinergic effects: dry mouth (approximately 14 percent), blurred vision (1 to 5 percent, dose-dependent), and constipation (approximately 3 percent), with an overall discontinuation rate of approximately 2 percent in controlled trials [6]. Serious adverse events are rare. This monograph reviews the chemistry, synthesis, and structural pharmacology of pirenzepine; the molecular pharmacology at muscarinic receptor subtypes; comprehensive human pharmacokinetics; the clinical evidence base across peptic ulcer and myopia indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a structured comparative assessment of five gastric antisecretory and muscarinic antagonist alternatives (telenzepine, atropine, cimetidine, ranitidine, omeprazole) against pirenzepine on five competency standards.